Alpha Tau shares are trading higher. The company announced the completion of enrollment in its ReSTART pivotal trial to treat recurrent cutaneous squamous cell carcinoma.

Benzinga Newsdesk www.benzinga.com Positive 87.0%

Neg 0% Neu 0% Pos 87%

Comments

No comments yet. Be the first!